# Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint

> **Open Intelligence Dossier** · First detected: 2026-09-22 21:00 UTC · Category: Business

## Executive Summary
11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint" is generating significant coverage in the Business category, with 11 articles from 11 distinct sources tracked by PULSE so far.


Outlets currently covering the story include MND Association, Investing.com India, Yahoo and Yahoo Finance. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| MND Association | Drug trial for rare genetic form of MND: results look 'encouraging' | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxPQjllQjJQNmEwbWw2UjZqc21Da2oyX200YUVad2RGQ19pZWhDWjJPdnRuWWlQQ3dsRHRJYVBGNEdJTkNuRDZ4ankyZlR4a082SG5uOWFmeUNjVFNGd3hUYk5pd0ZYVlhWQ0NSYTNadmg1Sm1ZQ1JWamFqT3NSTmo1MHdjaGp2dTdlN2dqaUF2ZXp4NkdjT3llNnpSSWF5cXE1U2dPb0hJX1Atdw?oc=5) |
| Investing.com India | Canaccord reiterates Ionis stock rating on positive trial results | [Source Link](https://news.google.com/rss/articles/CBMixAFBVV95cUxOQkloaElMOVYtWTFRQkVEWGJVckc1clZsV2tLaGVNS1ZZUy1HQ3JYYmJ3YWhkcWlCSEtQU0lRVF9HSm1tNUFtSHBxWGtWZEpjVUVRME1Sdkxvc2hleV92STZtTGRsTUthNWNCT1JGOFg0R2hReVBqSlJianc0TXZSV0RUa1BHWmt2bEUwY3dNQkdKb0JQWkYtTlN3LTZnR0IwVG5STTBBc1Z4QkU5ZTREU3hQbGFGeWJJVndaQnZiTjJ4MEZF?oc=5) |
| Yahoo | Otsuka and Ionis report positive data in Phase III FUSION trial of ulefnersen | [Source Link](https://news.google.com/rss/articles/CBMilwFBVV95cUxNMzhhN0RKVm1GdUdtM0Z3X0xxYlFwYV9Tbm5QTWk2WWx4NG9jMmY1VnZwTms3X1V1dDlUVEVzZGNMTTdnZVJZVElvSENid3d3akc2emZWOFlMTHZZX194XzctNFlwR0diQmF4Y091YUJqa0FMVHhuTzBHSmtKNjR1Sy1WTHJaeU5NV3JDaHUxQzVIblp2ck44?oc=5) |
| Yahoo Finance | Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxPdV8yb2dCOXo5cjdEc3VwbWI2M2txdkJyanFzVVFvWm5qMGNZVU9JNkdnUGdKYWJaal9kcFI4b1ZsS1FfWlNpS21CSEgwUUlGZUlWb3puQ3M3VE1VU2JLYnViYUdkc3oxZmtvaDR2cWVDUG5rZGlEUk01enhweFB0U3ZLN0lxM21lQ1l3ejZxY1F5NTgxT1hGREJGVkRqVlZ3ZURF?oc=5) |
| Neurology Advisor | Ulefnersen Shows Positive Phase 3 Results in FUS-ALS | [Source Link](https://news.google.com/rss/articles/CBMijwFBVV95cUxPSHFXMWFZQjFIajJEQUVwWlFOdXRZOXF4d3lVZF9qODhhMG9KTENqcjlwWENtNXlIRmVlUlpXLU5NTG53NlZ5VXpDVjVnWGxPb3BzTlVEUlJ4YVBvMlVRVllyLV9iNGx6ZEFuNlVGZkV0SjhLalRFd0Y1WERsV0NGcmphR0xad1Exb0ZzSWJjdw?oc=5) |
| FirstWord Pharma | Otsuka claims Phase III win for ulefnersen in rare genetic ALS | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE5jNVpsU0Z1a0c0YnhUbURPWm1kRnhOWkI3MFlGSDFzNWlqQ1hKdW9MRHo4YmtlRnFjTFNOOWVVejRteEZuZlRRQXpLUVJxOWoydHhj?oc=5) |
| PR Newswire | ALS Association Statement on Positive Phase 3 Results for Ulefnersen in FUS-ALS | [Source Link](https://news.google.com/rss/articles/CBMi0AFBVV95cUxON1JTVnBWNlVsSlY1eUZMNDFieUE5dVlDMnF3clVOZ3pPbXhYR3JDczRpSGhkdjRoOU1YS19pcm5KTlZDSHFoem1aaXdfZ1N6YXpzR3ZWVEFZWS1xMGd0NllVd1c0Nkh1dGtURWdaMmZwU0Vtalh4VHd0R2hvVjFpSldpMnFSN0sydllOeFlpczZKaXl3c2t1VzB5TkZiakJVTzd0QkRIVkE1RDZGOVVtQndoRHNfSE1ZN04zTVVqRUxBeFpjXzMwQkNJWTAya2JQ?oc=5) |
| Investing.com | Ionis drug meets primary goal in rare ALS gene mutation trial | [Source Link](https://news.google.com/rss/articles/CBMiugFBVV95cUxNRjJha2xUSGpZMnN4dFN5dGh1MXVycnlXWHVkVHNsUUI5dG1yRTVGODVGUGhwYkpWRWJIcFVUY0Ytd01JbnpYeGtKekdkb0RzYUVoTmZxTmRoLUp6aFNmX0dtYUV1WUh0aVlGbTZrTVByaU5VeVBqazFnTG80OEQwTXYwcG5nTV9oRFBGQnlsb25XWVhDZzdWaU1jU1pQVE9rdTM3SGxPR3ZtbDlBenZqUnpEVHZQd2J4Smc?oc=5) |
| TradingView | Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile | [Source Link](https://news.google.com/rss/articles/CBMi9AFBVV95cUxQSFl1Y0VBNW1NRUVNRGZoblh3QUlzaWZqSlMtVmVvTkVpeVExZkc1dEF0dzhjdFFPc3h4N0E4ekJNaVpWQWZEZTUxSWZlU3JzbURlT0xxRXYtZEh3SHdCTjkxREd1ZXE0S01rQXNRbGtqV1dJdkduNkNsRTY1R3pLYUs1dmNpVXJNdlViQ0hTUE9IaWszOWhVemtUMGJTMUNZYnl6WHp0NmxndktmWXRJbjFITy03U0xXQlVXNU5LT3p1S3dlSkhUVHhPYUIxRFpFZVZ6N3U0c0FEQXNCTndEMV9xTk9ycERWdG5jdi1Gd3oxTTUt?oc=5) |
| BioSpace | Otsuka Establishes Ulefnersen Early Access Program (EAP) for Eligible People Living with FUS-ALS | [Source Link](https://news.google.com/rss/articles/CBMizwFBVV95cUxPSDVQZktlOEFGOWo1YUNYWFVJbWpMbTVCajhIVTkyQUhtVTRTcmNqZDVpVHR2N01BQWZ2VE9VNXJHZExhaGtGbjRMOXNfLTBiTWt0eEdfS0xEWUh2NVU4V1lIVVAxaHRyQjdkYWNDd21sMk9KMklQZDgzWlJGQ1VaSFZTM3ZuQjNROFFocDFFZE1yUWRxaUpVOWhfb3pFUHBNTWNBd292bjRlTlRnZDdVM3ZwYlM3N1M0NlJvMmY3SzNzN21obnlpTU5xNGs5RTQ?oc=5) |
| Fierce Biotech | Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint | [Source Link](https://news.google.com/rss/articles/CBMirgFBVV95cUxQRXE5bXNhQzlYbkZaV0FxUkU3VkhiUnZiNDdnMERSUTdOX1AyejBLM3Y0WWw0STc3SGRGRzhQd3QxZ1BwN1UyWmh2NjBWUlRiZG9CenpNbjI5c3RYdmtad05aU3pBYTBBYWszSHE1OGNrM2YxTkpCU01fR3MwcktzakEtc3RldTZtTGhTYzEyTi1ybl9tN3VoTzR0bnNOM0taQ1VPLU9NdXl1NEh6dnc?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-22/otsuka-heads-to-fda-as-ionis-partnered-als-drug-hits-primary-phase-3-endpoint*